Apremilast for biologic-naive, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.

ABSTRACT: To evaluate the effect of the phosphodiesterase 4 inhibitor apremilast in biologic-naïve patients with early peripheral PsA in terms of disease activity, clinical manifestations, patient-perceived outcomes, as well as apremilast's safety profile in routine care settings of Greece. Non-interventional, multicenter, 52-week prospective cohort study, enrolling biologic-naïve patients with early active peripheral PsA who started apremilast after intolerance or inadequate response (within the first 12 months of treatment) to an initial conventional synthetic (cs)DMARD treatment. Non-responder imputation was applied for missing data.In total, 167 consecutive patients (mean age: 52.5 years; median PsA duration: 0.9 years) were analyzed. At baseline, the median (interquartile range) clinical Diseas

SUBMITTER: Sfikakis PP 

PROVIDER: S-EPMC10073163 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature